Tenofovir resistance-associated mutations at patients with chronic hepatitis B

Çakal B., Çavuş B., Bulakçı M., Güllüoğlu M., Akyüz F.

ESCV 2023 - 25th Annual Meeting of the European Society for Clinical Virology., Milan, İtalya, 30 Ağustos - 02 Eylül 2023, ss.141-142

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Basıldığı Şehir: Milan
  • Basıldığı Ülke: İtalya
  • Sayfa Sayıları: ss.141-142
  • İstanbul Üniversitesi Adresli: Evet

Özet

BACKGROUND-AIM

Tenofovir is a nucleotide analog that is widely used for the treatment of HBV all over the world due to its high potency and high

genetic barrier to resistance.

In this study, the presence of tS78T, rtA194T, and CYEI (S106C, H126Y, D134E, and L269I) and MLVV (rtL180M, rtT184L, rtA200V,

and rtM204V) mutations associated with tenofovir resistance in the gene encoding the reverse transcriptase (RT) enzyme was

investigated.

METHODS

Twenty treatment-naive patients who underwent liver biopsy due to chronic hepatitis B were included in this study. The gene

region encoding the HBV reverse transcriptase (RT) enzyme was amplified by PCR and sanger sequencing was performed (Table 1)

To identify viral genotypes and mutations in HBV Pol/RT gene regions, www.ncbi.nlm.nih.gov/projects/genotyping and

Geno2Pheno bioinformatics (https://hbv.geno2pheno.org/index.php) programs were used, respectively.

RESULTS

All (100%) HBV isolated from 20 patients with CHB were identified as genotype D

Tenofovir-associated mutations were detected in 6 patients (6/20, 30%). A194G mutations were detected in 1 (1/20, 5%) cases, and

H126R mutations were detected in 4 (4/20, 25%) cases, and D134N mutations were detected 1 (1/20, 5%).No MLBB (rtL180M,

rtT184L, rtA200V and rtM204V) mutations were detected in any patient (Table 2).

CONCLUSIONS

Identification of mutations related to potential TFD resistance in patients with treatment-naive chronic hepatitis B may contribute

to more effective treatment strategies.